This interview was conducted by Ann Menzie, MS, Senior Director, Evidence Synthesis, Modeling & Communication, Evidera, in conjunction with ongoing efforts to provide relevant and up-to-date information to help our clients develop and execute their evidence generation and market access strategies.
Ann recently spoke with Patrick about the evolution of the medical device industry, maturation of hospital value analysis programs, and driving value in healthcare by improving outcomes and quality while reducing costs. While this interview focuses on the changing medical device landscape and hospital purchasing dynamics in the US, formal value analysis through health technology assessments (HTAs) or tenders is well established ex-US. Many countries in Europe, for example, have implemented evidence-based, decision-making strategies to drive quality of care in a cost-constrained environment. By encouraging manufacturers of medical devices to consider the clinical and economic value of new products and the evidence strategies to support differentiating value propositions, there is substantial opportunity to address key stakeholders’ needs in all markets. While presented from the perspective of the US, the ideas expressed in this interview have global implications for clients looking to develop successful market access strategies worldwide.